39 results about "Eclampsia preeclampsia" patented technology

The invention discloses a construction method and application of a preeclampsia mouse animal model. According to the construction method, the m6A modification level in a mouse is reduced, and a mutant mouse with the reduced RNA m6A modification level, namely the preeclampsia mouse animal model, is obtained; specifically, a Mett13<+/>hybrid mutant mouse is constructed through an ES targeting technology, and a result shows that the sensitivity of the mutant mouse to a PE inducer L-NAME is increased, the mutant mouse presents the characteristics of PE, and a new thought and a new means are provided for etiological diagnosis, prevention and treatment of preeclampsia.

The invention discloses a novel peptidome for improving pre-eclampsia placental dysfunction, and relates to the related field of medicine. The novel peptidome solves the problem that most drugs for improving the pre-eclampsia placental dysfunction in the prior art have certain toxic and side effects on a mother womb. The peptidome has a sequence of Ac-RFAACAA-COOH, the peptidome is applied to drugs or medicaments for improving the pre-eclampsia placental dysfunction, the peptidome is applied to reduction of the level of urinary proteins/creatinine in pre-eclampsia pregnant rats, the peptidomeis applied to increase of the placental utilization rate of the pre-eclampsia pregnant rats, and the peptidome is applied to inversion of TNF alpha inhibition to migration and invasion of trophoblast.

The invention provides a method for diagnosing whether a subject has preeclampsia or is at the risk of preeclampsia, and further provides application of microRNA and/or a specific probe/detection primer of the microRNA in preparation of a diagnostic composition and the diagnostic composition for detecting preeclampsia. Expression of the microRNA in the plasma in a preeclampsia patient is obviously increased, and the microRNA can be used as a diagnostic index which is valuable, simple, convenient and easy to dynamically monitor preeclampsia; meanwhile, the increase of the microRNA in a placenta tissue is also a potential diagnostic index for predicting preeclampsia.

The invention discloses a method for detecting a high-density lipoprotein subcomponent in a preeclampsia judgment process, which comprises the following steps: presetting a high-density lipoprotein HDL subcomponent analysis kit, obtaining a blood sample, and detecting the to-be-detected blood sample by using the high-density lipoprotein HDL subcomponent analysis kit; carrying out standing centrifugal treatment on the blood sample, separating out plasma/serum, and adding the plasma/serum sample into a sample buffer solution containing lipophilic fluorescent dye, wherein the dye can be specifically combined with lipoprotein; injecting a gel dye into a microfluidic electrophoresis chip, adding a to-be-detected blood sample, performing detecting on a microfluidic electrophoresis chip analyzer,sending the sample into a separation channel under the action of an external electric field and electroosmotic flow, and separating HDL in the to-be-detected sample into a plurality of sub-componentsunder the action of a molecular sieve and charges. According to the structure, the judgment accuracy of preeclampsia is improved.

The invention belongs to the technical field of computer-aided diagnosis, and relates to a preeclampsia risk prediction method based on MLP multi-platform calibration. The method comprises the following steps: collecting sample data to obtain sample features; carrying out conversion and blank filling on the basic features of the sample; carrying out normalization processing on placenta growth factors in the disease sample data and the disease-free sample data and the processed basic features; constructing an MLP model for multi-platform calibration by using an MLP, and PlGF values of different measurement platforms after normalization are calibrated to the same platform; constructing a preeclampsia risk prediction model based on a random forest by using basic features in the processed disease sample data and disease-free sample data and placenta growth factors; and performing preeclampsia risk prediction on a test sample by using the constructed prediction model. The problem that the existing preeclampsia prediction means cannot meet the requirement for early screening is solved, and a reliable auxiliary tool is provided for doctors to clinically diagnose preeclampsia cases.

The invention provides a gene related to preeclampsia and application thereof, and belongs to the technical field of biological medicine. The gene is AC011753.5, and the AC011753.5 is highly expressed in a placenta of a patient with preeclampsia. By inhibiting the expression of AC011753.5 in human trophoblasts, the proliferation and invasion ability of the trophoblasts can be obviously promoted. Therefore, the compound can be used for preparing the medicine for treating preeclampsia.

The invention relates to the technical field of biological medicine, in particular to application of bone morphogenetic protein 6 in early diagnosis and treatment of preeclampsia. The invention provides application of BMP6 as a marker for early diagnosis/treatment of preeclampsia, application of BMP6 combined with PlGF and activin A in early diagnosis of preeclampsia, and application of BMP6 in preparation of drugs for prevention and treatment of preeclampsia. The invention finds that the BMP6, PlGF and activin A can improve the diagnosis effect of the existing diagnostic marker on preeclampsia in the preeclampsia early diagnosis; in addition, it is found that BMP6 can increase invasiveness and endothelial characteristic acquisition of human trophoblast cells, improve insufficient placental trophoblast invasion and poor vascular remodeling in the early stage of preeclampsia and then improve development of preeclampsia, and the BMP6 has the potential of preparing drugs for preventing and treating preeclampsia.

The present invention provides an application of a kidney-nourishing and fetus-cultivating pill in preparing a medicine for preventing preeclampsia. The kidney-nourishing and fetus-cultivating pill has a relatively good effect on preventing the preeclampsia, can obviously reduce preeclampsia morbidity of high-risk pregnant women in the preeclampsia, can inhibit progress of the disease into early-onset type preeclampsia, severe preeclampsia and gestational hypertension, improves maternal and infant outcome, reduces postpartum hemorrhage incidence, premature birth rate and neonatal NICU survivalrate, and increases neonatal body weight normality rate. The result shows that the kidney-nourishing and fetus-cultivating pill can improve pregnancy outcome of the pregnant women with high risk of the preeclampsia by preventing occurrence of the preeclampsia.

The invention discloses a preeclampsia diagnostic kit and application of nile blue. The preeclampsia diagnostic kit comprises a fluorescent dye for dyeing a blood sample of a pregnant woman. According to the preeclampsia diagnostic kit, a pregnant woman blood sample is dyed through a fluorescent dye, a normal pregnant woman blood sample and a preeclampsia pregnant woman patient blood sample are treated through the fluorescent dye in combination with the test of the embodiment part, by combining the FLIM technology, a blood sample of a normal pregnant woman and a blood sample of a preeclampsia pregnant woman patient can be obviously distinguished so that the preeclampsia can be diagnosed.

The invention provides a pre-eclampsia regulation and control analysis system based on machine learning, which comprises three testing mechanisms, namely a vibration frequency testing mechanism, an eye pupil area testing mechanism and a carbon dioxide content testing mechanism, a vibration testing device is arranged on a limb, an image acquisition device is arranged on glasses, and the carbon dioxide content testing mechanism is arranged on the limb. The carbon dioxide testing device is mounted in the mask, so that a user can be conveniently tested in real time; in the vibration frequency test, the frequencies are calibrated through the relationship among the frequencies, and a reference frequency value is obtained; in the image acquisition process, an image processing unit is used for carrying out sharpening processing on an image, and the pupil area is calibrated through a gray value; in a carbon dioxide test, a signal denoising unit is used for carrying out high-precision test on a carbon dioxide signal; and finally, the microprocessor establishes a prediction model according to the received carbon dioxide signal, the image information and the data of the frequency extraction unit, and the early warning analysis unit performs risk evaluation according to the prediction model.